Immunovant (IMVT) R&D In Process (2022 - 2023)
Immunovant filings provide 2 years of R&D In Process readings, the most recent being $12.5 million for Q2 2023.
- Quarterly R&D In Process changed N/A to $12.5 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Mar 2024, up 25.0% year-over-year, with the annual reading at $12.5 million for FY2024, 25.0% up from the prior year.
- R&D In Process hit $12.5 million in Q2 2023 for Immunovant, up from $10.0 million in the prior quarter.
- Across five years, R&D In Process topped out at $12.5 million in Q2 2023 and bottomed at $10.0 million in Q4 2022.